SWI QuickPicks Portfolio Up 29.2%

SWI QuickPicks Portfolio Up 29.2%

Los Angeles, Calif., November 23, 2016. Most analysts predicted the Dow to crash after election day. Instead it rose to a historical high on Wednesday. So did our SWI QuickPicks Portfolio; trading up another 1.2% adding 29.2% since inception. Even compared to a Dow historical high, we are doing just fine. As we have announced earlier, SWI has initiated three new stocks, which are now included in our SWI QuickPicks Portfolio.

Novocure (NVCR) is marketing its FDA approved Optune system and is testing new products in five (5) stage II/III clinical and nine (9) pre-clinical trials. NVCR is currently trading at $9.05 and has a BUY to STRONG BUY recommendation rating of 1.8 by four major analysts with a target price of $23.25.

Pfenex (PFNX) is a clinical-stage biotechnology company developing and commercializing high value

and difficult to manufacture proteins. The Company's initial focus is on biosimilar therapeutics and its

lead product is PF582, a biosimilar to Lucentis (ranibizumab). PFNX is currently trading at 10.05 and

has a a BUY recommendation rating of 1.8 by four major analysts with a target price of $20.00.

CytomX (CTMX) is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. The company uses the platform to create proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. CTMX is currently trading at $12.03 and has a a BUY recommendation rating of 1.8 by four major analysts with a target price of $20.00.

As usual the SWI QuickPicks Portfolio is outperforming the S&P significantly. Have a happy Thanksgiving weekend.

If you want to follow the companies that we are covering with more in depth research reports, go to our SWI Research site at www.swiresearch.com/report-index to download the reports, or visit www.stockwatchindex.com for up to date news on the covered companies. Please feel free to
re-distribute the reports to your friends and colleagues.

As a reminder; SWI QuickPicks is a combination of our own research with the consolidated opinions of several respected third party analysts.

Rainer Poertner - Chief Analyst

S tockWatchIndex and SWI Research (SWI) are not registered investment advisers and the information provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI has not been compensated for this report, is not holding any positions, or is intending to buy or sell the stock of any of the companies covered in this publication in the near future. The included information is subject to change without notice. Please visit www.swiresearch.com/#!legal-ease/lmvw1 for a full text of our Disclaimer, Privacy policy and Terms of Use.